Legal Opinion
Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc.
District Court, D. Delaware
Decided April 3, 2017No. Civil Action No. 1:14-cv-1043-RGA, Civil Action No. 1:14-cv-1196-RGA, Civil Action No. 1:14-cv-1289-RGAPublishedCited by 1 opinion
1Opinion of the Court
AMENDED TRIAL OPINION
ANDREWS, UNITED STATES DISTRICT JUDGE
Plaintiffs brought these patent infringement actions against Breckenridge Pharmaceutical, Inc., Roxane Laboratories, Inc.1, and Par Pharmaceutical, Inc. in 2014. (D.I. l).2 Breckenridge, Roxane, and Par each filed an Abbreviated New Drug Application (“ANDA”), seeking to engage in the commercial manufacture, use, and sale of generic versions of Novartis’s Zortress product. (D.I. 141-1, ¶¶44, 52, 59). Plaintiffs allege that these ANDAs infringe U.S. Patent No. 5,665,772 (“the ’772 patent”). Plaintiffs further allege that by filing these…
2Cases cited33 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
- Herbert Markman and Positek, Inc. v. Westview Instruments, Inc. And Althon Enterprises, Inc.Court of Appeals for the Federal Circuit · 1995
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Global-Tech Appliances, Inc. v. SEB S. A.Supreme Court of the United States · 2011
28 more not listed; retrieve them via the Exa API.
3Cited by1 opinion
- Pernix Ir. Pain Dac v. Alvogen Malta Operations Ltd.District Court, D. Delaware · 2018